Three investment firms topped the list of local tech investors in the DMV region according to CB Insights‘ report, The United States of Venture Capital.
An HIV-positive man in Britain has become the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.
Emmes today announced that Behrman Capital, a leading private equity firm, has made a significant investment in the company. The capital will allow Emmes, one of the Washington area’s top 100 largest private companies, to expand and strengthen its service offerings and international presence.
Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/19 to schedule your feedback session with BHI Entrepreneurs-in-Residence (who have industry experience in therapeutics, Dx, medtech and more) next Wednesday, March 20th. (The next session is scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here(“EIR resource” at BHI). For questions/more information, contact BHI.
More than 120 people registered for last week’s SBIR Workshop organized by BioHealth Innovation in partnership with Launch Workplaces and support from TEDCO and NIH FCU.
The event featured program overviews, “how to” sessions regarding specific aspects of proposal development and 1:1 partnering meetings with the program managers.
Speakers included: Todd Haim, Ph.D., Chief, Office of Small Business Research NIA; Mike Pieck, Ph.D., Small Business Coordinator, NHLBI; Maureen (Cusick) Thomas, Outreach Coordinator, NIA;Victor Prikhodko, Business Advisor, NIDA; Amir Rahbar, PhD, MBA, Program Director, NCI; Vladimir M. Popov, PhD, Business Dev. Manager, NCI-FNL;Amir Rahbar, PhD, MBA, Program Director, NCI; Henry Ahn, Program Director SBIR/STTR, NSF; and Colleen Gibney, SBIR Deputy Project Mgr, USAMRMC.
44% of the attendees had applied for SBIR funding before with half of these innovators receiving a Phase 1. Only 16% had received a Phase II award. The majority of attendees were from Montgomery and Frederick Counties and the City of Baltimore. However, registrants also traveled from Virginia, DC, Illinois and Pennsylvania.
Emergent BioSolutions announced today that the company has signed a deal with the U.S. Department of State to establish a supply chain for certain medical countermeasures that address chemical warfare agents.
New Enterprise Associates, the 41-year-old venture firm with offices in Menlo Park; San Francisco; Boston; New York; Chevy Chase, Md.; and Washington, D.C., is raising its biggest fund ever, shows a new SEC filing that shows target of $3.6 billion.
Office REIT Alexandria Real Estate Equities reports it has launched a new product geared to providing post-seed-stage life science companies with turnkey, fully furnished office/laboratory suites.
MaxCyte, the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement. Under the terms of the agreement, Kite will use MaxCyte’s Flow Electroporation® Technology to enable non-viral cell engineering for development of multiple CAR-T drug candidates for up to 10 targets.
Francis deSouza Photographer: Jeff Spicer/PA Wire via AP For years, the cost to decode a full human genome has been falling much like computer processing costs — from hundreds of thousands of dollars per person to about $1,000 today. With a $100 genome getting closer, the CEO of the top maker of DNA sequencers thinks the world may not be ready.